Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …

Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to
reduce platelet reactivity and to prevent thrombotic events in patients treated with …

Aims Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis
(ST) and bleeding, standardized and clinically validated thresholds for accurate risk …

For more than 10 years, dual antiplatelet therapy with aspirin and clopidogrel has remained
the cornerstone of treatment for patients with acute coronary syndrome (ACS). The novel …

Dual antiplatelet therapy—the combination of aspirin and a P2Y 12-receptor inhibitor—is the
cornerstone of treatment of patients with acute coronary syndromes (ACS) and of those …

Background and Purpose—Thromboembolic complications constitute a significant source of
morbidity after neurointerventional procedures. Flow diversion using the pipeline …

Background Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme might
be associated with increased activation of platelets. We aimed to assess the relationship …

P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the
secondary prevention of thrombotic events in vascular diseases. Within the past few years …

Antiplatelet agents, with aspirin and P2Y12 receptor antagonists as major key molecules,
are currently the cornerstone of pharmacological treatment of atherothrombotic events …

MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by
specific gene modifications. Platelets are the major source for circulating miRNAs, with …